Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL

被引:159
作者
Chiu, April
Xu, Weifeng
He, Bing
Dillon, Stacey R.
Gross, Jane A.
Sievers, Eric
Qiao, Xugang
Santini, Paul
Hyjek, Elizabeth
Lee, Joong-Won
Cesarman, Ethel
Chadburn, Amy
Knowles, Daniel M.
Cerutti, Andrea
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA
[2] Zymogenet Inc, Seattle, WA 98105 USA
[3] Cornell Univ, Weill Grad Sch Med Sci, Grad Program Immunol & Microbial Pathogenesis, New York, NY USA
关键词
D O I
10.1182/blood-2006-04-015958
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hodgkin lymphoma (HL) originates from the clonal expansion of malignant Hodgkin and Reed-Sternberg (HRS) cells. These B-cell-derived elements constitute less than 10% of the tumoral mass. The remaining tissue is comprised of an inflammatory infiltrate that includes myeloid cells. Myeloid cells activate B cells by producing BAFF and APRIL, which engage TACI, BCMA, and BAFF-R receptors on the B cells. Here, we studied the role of BAFF and APRIL in HL. Inflammatory and HRS cells from HL tumors expressed BAFF and APRIL. Unlike their putative germinal center B-cell precursors, HRS cells lacked BAFF-R, but expressed TACI and BCMA, a phenotype similar to that of plasmacytoid B cells. BAFF and APRIL enhanced HRS cell survival and proliferation by delivering nonredundant signals via TACI and BCMA receptors through both autocrine and paracrine pathways. These signals caused NF-kappa B activation; Bcl-2, Bcl-xL, and c-Myc up-regulation; and Bax downregulation, and were amplified by APRIL-binding proteoglycans on HRS cells. Interruption of BAFF and APRIL signaling by TACI-Ig decoy receptor, which binds to and neutralizes BAFF and APRIL, or by small-interfering RNAs targeting BAFF, APRIL, TACI, and BCMA inhibited HRS cell accumulation in vitro and might attenuate HL expansion in vivo. (c) 2007 by The American Society of Hematology
引用
收藏
页码:729 / 739
页数:11
相关论文
共 78 条
  • [1] Annunziata CM, 2000, BLOOD, V96, P2841
  • [2] [Anonymous], 2001, Neoplastic hematopathology
  • [3] Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
    Bargou, RC
    Emmerich, F
    Krappmann, D
    Bommert, K
    Mapara, MY
    Arnold, W
    Royer, HD
    Grinstein, E
    Greiner, A
    Scheidereit, C
    Dörken, B
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) : 2961 - 2969
  • [4] TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma
    Batten, M
    Fletcher, C
    Ng, LG
    Groom, J
    Wheway, J
    Laâbi, Y
    Xin, XG
    Schneider, P
    Tschopp, J
    Mackay, CR
    Mackay, F
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (02) : 812 - 822
  • [5] BLyS* and BLyS receptor expression in non-Hodgkin's lymphoma
    Briones, J
    Timmerman, JM
    Hilbert, DM
    Levy, R
    [J]. EXPERIMENTAL HEMATOLOGY, 2002, 30 (02) : 135 - 141
  • [6] Carbone A, 1998, BLOOD, V92, P2220
  • [7] EXPRESSION OF FUNCTIONAL CD30 ANTIGEN ON REED-STERNBERG CELLS AND HODGKINS-DISEASE CELL-LINES
    CARBONE, A
    GLOGHINI, A
    GATTEI, V
    ALDINUCCI, D
    DEGAN, M
    DEPAOLI, P
    ZAGONEL, V
    PINTO, A
    [J]. BLOOD, 1995, 85 (03) : 780 - 789
  • [8] TACI is mutant in common variable immunodeficiency and IgA deficiency
    Castigli, E
    Wilson, SA
    Garibyan, L
    Rachid, R
    Bonilla, F
    Schneider, L
    Geha, RS
    [J]. NATURE GENETICS, 2005, 37 (08) : 829 - 834
  • [9] Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF
    Craxton, A
    Magaletti, D
    Ryan, EJ
    Clark, EA
    [J]. BLOOD, 2003, 101 (11) : 4464 - 4471
  • [10] DALLAFAVERA R, 2001, LYMPHOMAS